MODEL VERDICT
Protalix BioTherapeutics, Inc. (PLX) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| Forward P/E 69 analyst estimates | $4.49 | +60.4% | 20% | A- | Analyst Est. |
| EV/EBITDA 42 industry peers | $2.35 | -16.1% | 20% | A- | Peer Data |
| Industry Median P/E 45 industry peers | $0.86 | -69.3% | 15% | A | Peer Data |
| Price / Free Cash Flow 43 industry peers | $1.84 | -34.3% | 15% | B+ | Peer Data |
| EV/EBIT 42 industry peers | $1.41 | -49.6% | 8% | B+ | Peer Data |
| EV/FCF 46 industry peers | $2.20 | -21.4% | 7% | B | Model Driven |
| EV To Revenue 182 industry peers | $7.05 | +151.8% | 4% | B | Data |
| Price / Sales 184 industry peers | $6.46 | +130.7% | 3% | B | Model Driven |
| Earnings Yield 47 industry peers | $0.93 | -66.8% | 2% | B | Data |
| FCF Yield 46 industry peers | $1.97 | -29.6% | 1% | B | Data |
| Weighted Output Blended model output | $2.85 | +1.8% | 100% | 79 | FAIRLY VALUED |
| EPS Growth ↓ | P/E Multiple → | 65× | 71× | 77× (Current) | 83× | 89× |
|---|---|---|---|---|---|
| Bear Case (4%) | $2 | $3 | $3 | $3 | $3 |
| Conservative (7%) | $3 | $3 | $3 | $3 | $3 |
| Base Case (10.0%) | $3 | $3 | $3 | $3 | $4 |
| Bull Case (14%) | $3 | $3 | $3 | $3 | $4 |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| EV/EBIT | 29.20 | 26.49 | 12.84 | 48.27 | 17.87 |
| EV/EBITDA | 25.76 | 26.46 | 12.94 | 37.87 | 12.48 |
| P/S Ratio | 1.62 | 1.39 | 0.89 | 2.85 | 0.71 |
Based on our peer multiples analysis with 24 valuation metrics, the model estimates PLX's fair value at $2.85 vs the current price of $2.80, implying +1.8% upside potential. Model verdict: Fairly Valued. Confidence: 79/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $2.85 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $2.03 (P10) to $3.32 (P90), with a median of $2.68.
PLX's current P/E of 76.5x compares to the industry median of 23.5x (45 peers in the group). This represents a +226.0% premium to the industry. The historical average P/E is N/Ax over 0 years. Signal: High Premium.
7 analysts cover PLX with a consensus rating of Buy. The consensus price target is N/A (range: N/A — N/A), implying N/A upside from the current price. Grade breakdown: Strong Buy (0), Buy (5), Hold (2), Sell (0), Strong Sell (0).
The model confidence score is 79/100, based on: data completeness (27), peer quality (25), historical depth (20), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows strong agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for PLX.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.